Century Therapeutics, Inc. (NASDAQ:IPSC) Given Consensus Rating of “Hold” by Brokerages

Century Therapeutics, Inc. (NASDAQ:IPSC) has been given an average rating of “Hold” by the seven brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $4.75.

A number of brokerages recently issued reports on IPSC. Wall Street Zen upgraded shares of Century Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Century Therapeutics in a report on Thursday, July 2nd. Finally, Mizuho began coverage on Century Therapeutics in a research report on Wednesday, May 27th. They set an “outperform” rating and a $8.00 price objective on the stock.

Century Therapeutics Price Performance

Shares of IPSC opened at $1.88 on Friday. The firm has a 50 day simple moving average of $2.06 and a 200-day simple moving average of $2.22. Century Therapeutics has a 1-year low of $0.43 and a 1-year high of $3.04. The stock has a market cap of $340.41 million, a price-to-earnings ratio of -2.02 and a beta of 1.59.

Century Therapeutics (NASDAQ:IPSC) last released its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). On average, equities analysts expect that Century Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Century Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Venture Management LLC bought a new stake in shares of Century Therapeutics during the first quarter worth approximately $27,495,000. BlackRock Inc. acquired a new position in Century Therapeutics in the second quarter valued at about $19,825,000. Commodore Capital LP acquired a new position in shares of Century Therapeutics in the 1st quarter valued at approximately $19,652,000. Seven Fleet Capital Management LP acquired a new stake in shares of Century Therapeutics in the 2nd quarter valued at $10,652,174. Finally, Trails Edge Capital Partners LP bought a new position in Century Therapeutics in the second quarter valued at about $10,130,674. 50.20% of the stock is owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for cancer and other serious diseases. The company uses induced pluripotent stem cell (iPSC) technology, gene editing and cell-engineering methods to create potentially off-the-shelf immune cell therapies designed to recognize and eliminate diseased cells.

Its pipeline has included engineered natural killer (NK) cell and T-cell programs targeting blood cancers. Among its leading programs is CNTY-101, an allogeneic CAR NK cell therapy directed at CD19, a target associated with certain B-cell malignancies.